Trial Title:
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
NCT ID:
NCT06128343
Condition:
Adenocarcinoma
Carcinoma
Neoplasms
Conditions: Official terms:
Adenocarcinoma
Conditions: Keywords:
Adenocarcinoma
fine-needle aspiration
endoscopic ultrasonography
epidemiology
biobank
DNA tumors
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
collection of biological samples
Description:
Collection of biological samples including whole blood and micro-biopsy from tissue of
pancreas
Summary:
BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including
clinical data and biological samples from tumor. The aim is to enrich the previous
propective collection BACAP in order to support future research projects.
Detailed description:
Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In
over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for
pancreatic cancer remains the surgical exeresis. This one can only be suggested as a
curative treatment in only 10 to 15% of cases. Besides, prevention or screening is
difficult to set up due to the absence of clearly identified risk factors or groups and
to the absence of useful markers for the diagnosis in clinical practice.
The research efforts in this area must face a double challenge: saving time while
improving the diagnosis period and strengthen the therapeutic equipment. It is important
to identify and characterise the new molecular markers applicable for a better diagnosis
and/or treatment (especially the response factors to chemotherapy).
The present project aims to enrich with fresh tumor tissue and somatic genetic analysis
the existing propective collection BACAP in order to support support future research
projects on:
- the development of new diagnostic tools,
- understanding the development of tumors of the pancreas
- the development of new therapeutic targets
- understanding the response to chemotherapy...
Criteria for eligibility:
Study pop:
Patients with a pancreatic adenocarcinoma proven cytologically or histologically without
any treatment
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patient with pancreatic mass syndrome explored by ultrasound endoscopy with
cytopuncture or
- Patient with pancreatic mass syndrome explored by an abdominal scanner with and
without injection of product contrast and/or puncture of the mass or secondary
lesions by radiological route or
- Patient with pancreatic adenocarcinoma proven histologically and/or cytologically
Exclusion Criteria:
- Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
- Pregnant or breastfeeding patient
Gender:
All
Minimum age:
18 Years
Maximum age:
120 Years
Locations:
Facility:
Name:
Haut-Lévêque Hospital
Address:
City:
Bordeaux
Zip:
33604
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Véronique VENDRELY, MD
Phone:
(0)5 57 62 33 13
Phone ext:
+33
Email:
veronique.vendrely@chu-bordeaux.fr
Facility:
Name:
Béthune hospital center
Address:
City:
Béthune
Zip:
62408
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Hélène VANDAMME, MD
Email:
hvandamme@ch-bethune.fr
Facility:
Name:
Huriez Hospital
Address:
City:
Lille
Zip:
59037
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Guillaume PIESSEN, MD
Phone:
(0)3 20 44 44 07
Phone ext:
+33
Email:
Guillaume.PIESSEN@CHRU-LILLE.FR
Investigator:
Last name:
Stépahnie TRUANT, MD
Email:
Principal Investigator
Investigator:
Last name:
Guillaume PIESSEN, MD
Email:
Principal Investigator
Facility:
Name:
Jean Mermoz private hosptila
Address:
City:
Lyon
Zip:
69008
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Bertrand NAPOLEON, MD
Phone:
(0)4 78 75 67 43
Phone ext:
+33
Email:
dr.napoleon@wanadoo.fr
Investigator:
Last name:
Pascal ARTRU, MD
Email:
Sub-Investigator
Investigator:
Last name:
Bertrand PUJOL, MD
Email:
Sub-Investigator
Investigator:
Last name:
Fabien FUMEX, MD
Email:
Sub-Investigator
Investigator:
Last name:
Jérôme DESRAME, MD
Email:
Sub-Investigator
Investigator:
Last name:
Gérard LLEDO, MD
Email:
Sub-Investigator
Investigator:
Last name:
Christine LEFORT, MD
Email:
Sub-Investigator
Investigator:
Last name:
Vincent LEPILLIEZ, MD
Email:
Sub-Investigator
Facility:
Name:
Saint Eloi Hospital
Address:
City:
Montpellier
Zip:
34295
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Eric ASSENAT, MD
Email:
e-assenat@chu-montpellier.fr
Facility:
Name:
Regional Cancer Center From Montpellier
Address:
City:
Montpellier
Zip:
34298
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Nicolas FLORI, MD
Phone:
(0)4 67 61 85 13
Phone ext:
+33
Email:
Nicolas.Flori@montpellier.unicancer.fr
Facility:
Name:
PAU hospital
Address:
City:
Pau
Zip:
6400
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Philippe BARTHELEMY, Md
Phone:
(0)5 59 72 67 72
Phone ext:
+33
Email:
philippe.berthelemy@ch-pau.fr
Facility:
Name:
Rangueil hospital
Address:
City:
Toulouse
Zip:
31059
Country:
France
Status:
Recruiting
Contact:
Last name:
Barbara BOURNET, MD, PhD
Phone:
(0)5 61 32 32 35
Phone ext:
+33
Email:
bournet.b@chu-toulouse.fr
Investigator:
Last name:
Nicolas CARRERE, MD
Email:
Sub-Investigator
Investigator:
Last name:
Fabrice MUSCARI, MD
Email:
Sub-Investigator
Investigator:
Last name:
Rosine GUIMBAUD, MD
Email:
Sub-Investigator
Investigator:
Last name:
Corinne COUTEAU, MD
Email:
Sub-Investigator
Investigator:
Last name:
Marion DESLANDRES, MD
Email:
Sub-Investigator
Investigator:
Last name:
Pascale RIVERA, MD
Email:
Sub-Investigator
Investigator:
Last name:
Marion JAFFRELOT, MD
Email:
Sub-Investigator
Investigator:
Last name:
Nadim FARES, MD
Email:
Sub-Investigator
Start date:
November 16, 2023
Completion date:
February 28, 2035
Lead sponsor:
Agency:
University Hospital, Toulouse
Agency class:
Other
Source:
University Hospital, Toulouse
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06128343
